1. Vitamin D Related/Nuclear Receptor Autophagy
  2. Androgen Receptor Autophagy
  3. Enzalutamide

Enzalutamide (MDV3100) est un récepteur des androgènes (AR) avec un IC50 de 36 nM dans les cellules prostatiques LNCaP. Enzalutamide est un activateur d'autophagie.

Enzalutamid (MDV3100) ist ein androgen receptor (AR)-Antagonist mit einem IC50-Wert von 36 nM in LNCaP-Prostatazellen. Enzalutamid ist ein autophagy-Aktivator.

Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator.

For research use only. We do not sell to patients.

Enzalutamide Chemical Structure

Enzalutamide Chemical Structure

CAS No. : 915087-33-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg In-stock
1 g In-stock
2 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 187 publication(s) in Google Scholar

Other Forms of Enzalutamide:

Top Publications Citing Use of Products

161 Publications Citing Use of MCE Enzalutamide

WB
IF

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2018 Sep 5;157:1164-1173.  [Abstract]

    Dose-response curves of active degraders and Enzalutamide on AR transcriptional activity as measured in LNCaP-eGFP cells following 0.1 nM R1881 for 72 hours in RPMI+CSS media (3 replicates per point). (B) PSA inhibition curves against transcriptional activity of AR as measured from the media of LNCaP-eGFP cells with active degraders and enzalutamide under the same conditions as A.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Int J Cancer. 2018 Aug 1;143(3):645-656.  [Abstract]

    Evaluation of protein expression change of Notch receptors response to the treatment of 10 μM Enzalutamide as an androgen receptor (AR) antagonist.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2018 Sep 14;293(37):14328-14341.  [Abstract]

    C4-2R cells are treated with MK 733, Enzalutamide or combination of the two drugs at the indicated concentrations for 48 hours, followed by Immunoblotting (IB) against cleaved PARP.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Oct 10;8(1):15063.  [Abstract]

    The increased protein levels of both LEDGF/p75 and CLU are observed in cells treated with either 1 nM or 10 nM DHT, which is attenuated by exposure to 1 μM Enz.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Nov 23;8(1):17307.   [Abstract]

    Protein expression analysis of p-STAT3S727, STAT3, PSA, AR and Vinculin in the treatment of ENZ and GPA500.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Nov 23;8(1):17307.   [Abstract]

    Western analysis of protein expression in LNCaP and 16D CRPC cells treated with 10 μM ENZ for indicated days.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Front Physiol. 2018 Apr 16;9:312.  [Abstract]

    Protein lysates of vehicle-, 1 μM BCT-, and 1 μM EZT-treated MDA-MB-453 cells are probed by immunoblotting with anti-KCa1.1 (upper panel) and anti-ACTB (lower panel) antibodies on the same filter.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: J Endocrinol. 2018 Oct 1;JOE-18-0503.R1.  [Abstract]

    At the protein level, CORT-induced FKBP5 content in both WAT and liver is attenuated with AR antagonism.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2017 Jan;7(1):54-71.  [Abstract]

    BRN2 expression inversely correlates with PSA in human PCa and is induced by ENZ. Protein and relative mRNA expression of BRN2, SYP, NSE, CGA, and VINC in siScr and 796 siBRN2 16DCRPC cells treated -/+ 10 μM ENZ for 2, 4 or 7 days.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2017 Oct;16(10):2281-2291.  [Abstract]

    Top-Cells (RPMI+CSS) are co-transfected with ARR3tk-Luc and Renilla-Luc plasmids (48 hrs). With the exception of 22Rv1, 0.1 nM R1881 is used to stimulate the AR, followed by compound treatment (24 hrs). 100% refers to normalized luminescence without compound (DMSO vehicle). Curves are fitted to a sigmoid dose-response with variable slope equation (GraphPad).

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Int J Oncol. 2017 Jan;50(1):75-84.  [Abstract]

    Effects of culture in CSS and treatment with Enzalutamide on cell cycle of T24GR cells. T24 and T24GR cells (5x105) are seeded in a 6-well plate and cultured for 24 h. The culture medium is changed to that containing 50 μM Enzalutamide or vehicle (DMSO). Seventy-two hours later, cell lysates are harvested and subjected to western blot analysis for cyclin B1, D1 and β-actin.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Horm Cancer. 2017 Aug;8(4):243-256.  [Abstract]

    LNCaP cells are grown in complete media for 24 h in the presence of vehicle (control) or Enzalutamide, 10 μM, and protein expression normalized to β-tubulin.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Prostate. 2017 Feb;77(3):309-320.  [Abstract]

    LNCaP cell are treated with 20 mM LY294002 or 10 mM U0126 for 1 hr before 10 mM of ENZ. Whole-cell extracts are subjected to SDS–PAGE, followed by western blot analysis for the indicated proteins.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Department of Medicine, Faculty of Obstetrics and Gynaecology. University of British Columbia. 2017 Apr.

    VCaP (mock) and VCaP (UGT2B17) cells are cultured in the RPMI1640 medium plus 5% CSS. Cells are treated with vehicle, 10 nM of R1881 or 10 μM of Enzalutamide (ENZ) for 0 or 28 days. Protein levels of UGT2B17, pSrc, tSrc, pAKT, total AKT, pSTAT3, total STAT3, pSTAT5, total STAT5 and β-actin are determined by immunoblotting.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Faculty of Medicine. University of British Columbia. 2017 Dec.

    p-TNIK (S764), T-TNIK, and PSA protein expression are assessed in (A) LNCaP and 16DCRPC cells that are treated with 10 μM Enzalutamide (ENZ) in media containing 10% FBS for 2, 4, and 7 days by western blot. Vinculin is used as loading control.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Dec 7;8(70):115054-115067.  [Abstract]

    The levels of YAP1 protein are measured in LNCaP cells treated for 24 h with the AR antagonist MDV3100 (Enzalutamide, 100 nM) and ICI 176334 (10 mM).

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2016 Sep;15(9):2107-18.  [Abstract]

    Combination of Enzalutamide and 17-AAG lead to decreased AR protein level and transcriptional activity. (A&B) LNCaP (A) and C4-2 (B) cells are treated as indicated for 24 hr, followed by IB against AR, PSA and CHIP. (C&D) 22RV1 (C) and MR49F (D) cells are treated as indicated for 24 hr, followed by IB against AR and HSP90. (E) C4-2 cells are treated as indicated for 24 hr, fractionated into cytoplasm and nuclear, followed by IB against AR and Plk1.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2016 Jun;14(6):574-85.  [Abstract]

    LNCaP and DuCaP cells are 1 treated for 72 hours with 1 or 10 μM Enzalutamide in the presence of increasing IL6 concentrations. The effect on JAK/STAT3 signaling is measured by determining STAT3 Tyr705-phosphorylation via Western blot and calculation of dose response curves.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Sep 13;7(37):59781-59794.  [Abstract]

    Short term treatment (14 days) of LAPC4 vehicle cells with 8μM Enzalutamide clearly demonstrates that AR overexpression is not a short term effect of drug treatment but develops as a long term adaptation during acquisition of resistance. It has been suggested that presence of a truncated AR variant (AR-V7) is associated with resistance to Enzalutamide.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Jun 28;7(26):40690-40703.  [Abstract]

    DHT alone, Enzalutamide alone, or the combination in androgen-depleted conditions also increase expression of canonical AR targets: KLK3, TMPRSS2, and NKX3.1 and increase protein levels of PSA encoded by the KLK3 gene.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Oncotarget. 2015 Aug 21;6(24):20474-84.  [Abstract]

    LNCaP cells are cultured in RPMI1640 medium containing 5% CSS and treated with vehicle, 1 μM of ICRF187 or 1 μM of ICRF193 in addition to vehicle, 10 nM of R1881 or 10 μM of ENZ treatment for 2 hours. Three independent ChIP experiments are performed using the AR antibody. AR protein levels under 2 and 24 hour treatment are detected by Western blotting.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Patent. US20140088178A1.

    Effect of AR1 (MDV-3100) administration on AKT and ERK phosphorylation and protein levels in LNCaP cells. (A), 10 μM AR1. (B), after 48 hours of AR1 treatment at indicated concentrations. (C), Dose dependent change of expression level of AKT or ERK after treatment with AR1. (D), Dose dependent change of expression level of AKT or ERK after treatment with AR1.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Cancer Res. 2013 Aug 15;73(16):5206-17.  [Abstract]

    MDV3100-induced CLU is mediated via p90Rsk-YB-1 signaling pathway. MDV3100 activates AKT and MAPK pathways. LNCaP cells are treated with 10 μM MDV3100 for indicated times and Western blotted using CLU, p-Rsk/R/Rsk, p-S6K/S6K, and pYB-1/YB-1. Vinculin is used as a loading control.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Cancer Res. 2013 Aug 15;73(16):5206-17.  [Abstract]

    CLU is induced by MDV3100 in time- and dose-dependent manner. LNCaP cells are treated with MDV3100 at indicated time (left) or concentration (right) and Western blot analysis is conducted with CLU, AR, and PSA antibodies.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2013 May;12(5):567-76.  [Abstract]

    LNCaP cells are treated with Compound 30 or MDV3100 for 24 hours; AR and PSA are analyzed by Western blot analysis; Vinculin is used as a loading control.

    Enzalutamide purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2013 May;12(5):567-76.  [Abstract]

    LNCaP cells are maintained in androgen-deprived conditions for 24 hours and treated with 10 μM Compound 30 or MDV3100 for 2 hours followed by addition of 1 nM of R1881. After 15 minutes incubation, cells are fixed and AR localization is assessed by immunofluorescence imaging.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator[1][2].

    IC50 & Target

    IC50: 36 nM (androgen-receptor, in LNCaP cells)[1]

    Cellular Effect
    Cell Line Type Value Description References
    CWR22R IC50
    > 10 μM
    Compound: 4
    Cytotoxicity against AR-positive human 22Rv1 cells assessed as inhibition of cell growth incubated for 7 days in regular culture medium by WST-8 assay
    Cytotoxicity against AR-positive human 22Rv1 cells assessed as inhibition of cell growth incubated for 7 days in regular culture medium by WST-8 assay
    [PMID: 30629437]
    CWR22R IC50
    > 30 μM
    Compound: Enza
    Antiproliferative activity against human 22Rv1 expressing AR assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
    Antiproliferative activity against human 22Rv1 expressing AR assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
    [PMID: 31437779]
    CWR22R IC50
    > 30 μM
    Compound: Enza
    Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay
    Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay
    [PMID: 30925341]
    CWR22R GI50
    > 40 μM
    Compound: Enzalutamide
    Antiproliferative activity against AR-positive human 22Rv1 cells harboring ARE14 construct assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay
    Antiproliferative activity against AR-positive human 22Rv1 cells harboring ARE14 construct assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay
    [PMID: 31271960]
    CWR22R IC50
    24.77 μM
    Compound: 2a
    Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining-based fluorescence assay
    Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining-based fluorescence assay
    [PMID: 30108852]
    CWR22R GI50
    3.34 μM
    Compound: MDV3100
    Growth inhibition of human CWR22Rv1 cells by MTT assay
    Growth inhibition of human CWR22Rv1 cells by MTT assay
    [PMID: 25634130]
    CWR22R IC50
    31.76 μM
    Compound: 4
    Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay
    Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay
    [PMID: 27301368]
    CWR22R IC50
    31.76 μM
    Compound: 5; MDV3100; Xtandi; Enzalutamide
    Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay
    Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay
    [PMID: 27131065]
    CWR22R IC50
    31.76 μM
    Compound: Enzalutamide
    Antiproliferative activity against human 22Rv1 cells after 96 hrs by Oncotest monolayer assay
    Antiproliferative activity against human 22Rv1 cells after 96 hrs by Oncotest monolayer assay
    [PMID: 26965862]
    CWR22R IC50
    31.8 μM
    Compound: 2; MDV3100
    Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay
    Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay
    [PMID: 31288149]
    CWR22R IC50
    36.66 μM
    Compound: Enzalutamide
    Antiproliferative activity against human 22Rv1 cells measured after 96 hrs by celltiter-glo assay
    Antiproliferative activity against human 22Rv1 cells measured after 96 hrs by celltiter-glo assay
    [PMID: 30964293]
    CWR22R IC50
    36.66 μM
    Compound: Enzalutamide
    Antiproliferative activity against human 22Rv1 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human 22Rv1 cells after 72 hrs by Cell-Titer Glo assay
    [PMID: 29448139]
    CWR22R IC50
    36.66 μM
    Compound: Enzalutamide
    Antiproliferative activity against human 22Rv1 cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human 22Rv1 cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
    [PMID: 34121397]
    CWR22R IC50
    36.66 μM
    Compound: Enz
    Antiproliferative activity against AR-positive human 22Rv1 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay
    Antiproliferative activity against AR-positive human 22Rv1 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay
    [PMID: 29566488]
    CWR22R IC50
    36.66 μM
    Compound: Enzalutamide
    Antiproliferative activity against human 22Rv1 cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay
    Antiproliferative activity against human 22Rv1 cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay
    [PMID: 29758518]
    CWR22R IC50
    42.3 μM
    Compound: ENZ
    Antiproliferative activity against AR-positive human 22RV1 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against AR-positive human 22RV1 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    [PMID: 33756125]
    CWR22R IC50
    46.27 μM
    Compound: ENZa
    Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 36031018]
    CWR22R IC50
    9.7 μM
    Compound: 3, MDV3100
    Inhibition of cell survival in human CWR22Rv1 cells after 144 hrs by TUNEL assay
    Inhibition of cell survival in human CWR22Rv1 cells after 144 hrs by TUNEL assay
    [PMID: 25121586]
    DU-145 GI50
    > 10 μM
    Compound: enzalutamide
    Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 34908406]
    DU-145 IC50
    32.27 μM
    Compound: 4
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay
    [PMID: 27301368]
    DU-145 IC50
    32.27 μM
    Compound: 5; MDV3100; Xtandi; Enzalutamide
    Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay
    Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay
    [PMID: 27131065]
    DU-145 IC50
    32.3 μM
    Compound: 2; MDV3100
    Antiproliferative activity against human DU145 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay
    Antiproliferative activity against human DU145 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay
    [PMID: 31288149]
    DU-145 IC50
    44.55 μM
    Compound: 2a
    Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining-based fluorescence assay
    Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining-based fluorescence assay
    [PMID: 30108852]
    DU-145 IC50
    44.7 μM
    Compound: Enzalutamide
    Antiproliferative activity against human DU145 cells measured after 72 hrs by celltiter-glo assay
    Antiproliferative activity against human DU145 cells measured after 72 hrs by celltiter-glo assay
    [PMID: 30964293]
    DU-145 IC50
    45.3 μM
    Compound: ENZ
    Antiproliferative activity against AR-negative human DU145 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against AR-negative human DU145 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    [PMID: 33756125]
    DU-145 IC50
    46.1 μM
    Compound: Enzalutamide
    Antiproliferative activity against human DU145 cells after 3 days by MTT assay
    Antiproliferative activity against human DU145 cells after 3 days by MTT assay
    [PMID: 29117897]
    DU-145 IC50
    46.1 μM
    Compound: Enzalutamide
    Antiproliferative activity against AR negative human DU145 cells after 3 days by MTT assay
    Antiproliferative activity against AR negative human DU145 cells after 3 days by MTT assay
    [PMID: 27810589]
    DU-145 IC50
    49.3 μM
    Compound: MDV3100
    Antiproliferative activity against human DU-145 cells assessed as reduction in cel viability after 72 hrs by MTT assay
    Antiproliferative activity against human DU-145 cells assessed as reduction in cel viability after 72 hrs by MTT assay
    [PMID: 32169785]
    GES1 IC50
    96.89 μM
    Compound: Enz
    Cytotoxicity against human GES1 cells assessed as inhibition of cell proliferation by MTT assay
    Cytotoxicity against human GES1 cells assessed as inhibition of cell proliferation by MTT assay
    [PMID: 36154033]
    HEK293 IC50
    0.216 μM
    Compound: 5
    Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay
    Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay
    [PMID: 30525603]
    L02 IC50
    17.1 μM
    Compound: Enza
    Cytotoxicity against human L02 assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
    Cytotoxicity against human L02 assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
    [PMID: 31437779]
    L02 IC50
    17.1 μM
    Compound: Enza
    Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay
    Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay
    [PMID: 30925341]
    LNCaP IC50
    > 100 μM
    Compound: Enzalutamide
    Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days
    Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days
    [PMID: 23301637]
    LNCaP IC50
    0.1 μM
    Compound: ENZ
    Inhibition of prostate specific antigen expression in human LNCaP cells expressing ARR2PB-eGFP by immunoassay
    Inhibition of prostate specific antigen expression in human LNCaP cells expressing ARR2PB-eGFP by immunoassay
    [PMID: 35077161]
    LNCaP IC50
    0.19 μM
    Compound: Enza
    Antiproliferative activity against human LNCAP expressing AR assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
    Antiproliferative activity against human LNCAP expressing AR assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
    [PMID: 31437779]
    LNCaP IC50
    0.48 μM
    Compound: Enz
    Inhibition of PSA secretion in human LNCaP ARR2PB-eGFP cells measured after 3 days by immuno assay
    Inhibition of PSA secretion in human LNCaP ARR2PB-eGFP cells measured after 3 days by immuno assay
    [PMID: 36154033]
    LNCaP IC50
    1.31 μM
    Compound: Enzal
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by MTT assay
    [PMID: 30743097]
    LNCaP IC50
    1.9 μM
    Compound: Enzalutamide
    Antiproliferative activity against hormone sensitive human LNCaP cells assessed as reduction in cell proliferation measured after 6 days by CellTiter-Glo assay
    Antiproliferative activity against hormone sensitive human LNCaP cells assessed as reduction in cell proliferation measured after 6 days by CellTiter-Glo assay
    [PMID: 33388655]
    LNCaP IC50
    11.47 μM
    Compound: 4
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay
    [PMID: 27301368]
    LNCaP IC50
    11.47 μM
    Compound: 5; MDV3100; Xtandi; Enzalutamide
    Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay
    Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay
    [PMID: 27131065]
    LNCaP IC50
    11.5 μM
    Compound: 2; MDV3100
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay
    [PMID: 31288149]
    LNCaP IC50
    12.5 μM
    Compound: Enzalutamide
    Antiproliferative activity against human LNCAP cells after 3 days by MTT assay
    Antiproliferative activity against human LNCAP cells after 3 days by MTT assay
    [PMID: 29117897]
    LNCaP IC50
    127.1 nM
    Compound: 4
    Antiproliferative activity against human LNCAP cells after 3 days
    Antiproliferative activity against human LNCAP cells after 3 days
    [PMID: 26046313]
    LNCaP IC50
    133 nM
    Compound: Enzalutamide
    Growth inhibition of human LNCaP cells carrying AR T878A mutant assessed as cell viability by WST-8 assay
    Growth inhibition of human LNCaP cells carrying AR T878A mutant assessed as cell viability by WST-8 assay
    [PMID: 34473519]
    LNCaP IC50
    133 nM
    Compound: 2
    Growth inhibition of human LNCaP cells assessed as cell viability measured after 4 days in presence of R1881 by WST-8 assay
    Growth inhibition of human LNCaP cells assessed as cell viability measured after 4 days in presence of R1881 by WST-8 assay
    [PMID: 34431670]
    LNCaP IC50
    150.8 nM
    Compound: Enzalutamide
    Antiproliferative activity against AR-positive human LNCAP cells incubated for 7 days in presence of AR agonist, R1881 by WST-8 assay
    Antiproliferative activity against AR-positive human LNCAP cells incubated for 7 days in presence of AR agonist, R1881 by WST-8 assay
    [PMID: 31804827]
    LNCaP IC50
    16.5 μM
    Compound: MDV3100
    Antiproliferative activity against human LNCaP cells assessed as reduction in cel viability after 72 hrs by MTT assay
    Antiproliferative activity against human LNCaP cells assessed as reduction in cel viability after 72 hrs by MTT assay
    [PMID: 32169785]
    LNCaP IC50
    17.6 μM
    Compound: ENZ
    Antiproliferative activity against AR-positive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against AR-positive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    [PMID: 33756125]
    LNCaP EC50
    180 nM
    Compound: 4
    Inhibition of DHT-induced androgen receptor transactivation in human LNCaP cells after 24 hrs by luciferase reporter gene assay relative to control
    Inhibition of DHT-induced androgen receptor transactivation in human LNCaP cells after 24 hrs by luciferase reporter gene assay relative to control
    [PMID: 27437082]
    LNCaP GI50
    2.88 μM
    Compound: MDV3100
    Growth inhibition of human LNCAP cells by MTT assay
    Growth inhibition of human LNCAP cells by MTT assay
    [PMID: 25634130]
    LNCaP IC50
    20.9 μM
    Compound: 2a
    Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining-based fluorescence assay
    Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining-based fluorescence assay
    [PMID: 30108852]
    LNCaP IC50
    25 nM
    Compound: 4
    Cytotoxicity against AR-positive human LNCaP cells assessed as inhibition of cell growth incubated for 7 days in presence of AR agonist, R1881 in charcoal stripped medium by WST-8 assay
    Cytotoxicity against AR-positive human LNCaP cells assessed as inhibition of cell growth incubated for 7 days in presence of AR agonist, R1881 in charcoal stripped medium by WST-8 assay
    [PMID: 30629437]
    LNCaP IC50
    26.32 μM
    Compound: Enz
    Cytotoxicity against human LNCAP cells assessed as inhibition of cell proliferation by MTT assay
    Cytotoxicity against human LNCAP cells assessed as inhibition of cell proliferation by MTT assay
    [PMID: 36154033]
    LNCaP IC50
    33.84 μM
    Compound: Enzalutamide
    Antiproliferative activity against human LNCAP cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human LNCAP cells after 72 hrs by Cell-Titer Glo assay
    [PMID: 29448139]
    LNCaP IC50
    33.84 μM
    Compound: Enz
    Antiproliferative activity against AR-positive human LNCAP cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay
    Antiproliferative activity against AR-positive human LNCAP cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay
    [PMID: 29566488]
    LNCaP IC50
    4.85 μM
    Compound: 4
    Antiproliferative activity against human LNCAP cells after 7 days by MTT assay
    Antiproliferative activity against human LNCAP cells after 7 days by MTT assay
    [PMID: 27437082]
    LNCaP IC50
    42.37 μM
    Compound: Enzalutamide
    Antiproliferative activity against human LNCAP cells measured after 96 hrs by celltiter-glo assay
    Antiproliferative activity against human LNCAP cells measured after 96 hrs by celltiter-glo assay
    [PMID: 30964293]
    LNCaP IC50
    42.37 μM
    Compound: Enzalutamide
    Antiproliferative activity against human LNCaP cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human LNCaP cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
    [PMID: 34121397]
    LNCaP IC50
    42.37 μM
    Compound: Enzalutamide
    Antiproliferative activity against human LNCAP cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay
    Antiproliferative activity against human LNCAP cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay
    [PMID: 29758518]
    LNCaP IC50
    437 nM
    Compound: 1
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability measured after 6 days by CellTiter-Glo assay
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability measured after 6 days by CellTiter-Glo assay
    [PMID: 36070471]
    LNCaP GI50
    5.12 μM
    Compound: 6, MDV3100
    Cytotoxicity against human LNCAP cells after 7 days by MTT assay
    Cytotoxicity against human LNCAP cells after 7 days by MTT assay
    [PMID: 23713567]
    LNCaP IC50
    5336 nM
    Compound: Enza
    Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay
    Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay
    [PMID: 30925341]
    LNCaP IC50
    7.9 μM
    Compound: ENZa
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 30711833]
    LNCaP EC50
    915 nM
    Compound: 6, MDV3100
    Displacement of [3H]R1881 from AR in human LNCaP cells after 2 hrs by scintillation counting analysis
    Displacement of [3H]R1881 from AR in human LNCaP cells after 2 hrs by scintillation counting analysis
    [PMID: 23713567]
    LNCaP C4-2 GI50
    > 40 μM
    Compound: Enzalutamide
    Antiproliferative activity against AR-positive human C4-2 cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay
    Antiproliferative activity against AR-positive human C4-2 cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay
    [PMID: 31271960]
    LNCaP C4-2B IC50
    17.96 μM
    Compound: Enz
    Antiproliferative activity against AR-positive human C4-2B cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay
    Antiproliferative activity against AR-positive human C4-2B cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay
    [PMID: 29566488]
    LNCaP C4-2B IC50
    20.77 μM
    Compound: Enzalutamide
    Antiproliferative activity against human C4-2B cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay
    Antiproliferative activity against human C4-2B cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay
    [PMID: 29758518]
    LNCaP C4-2B IC50
    22.17 μM
    Compound: 1
    Antitumor activity against enzalutamide-resisitant human C4-2B cells administered for 3 months
    Antitumor activity against enzalutamide-resisitant human C4-2B cells administered for 3 months
    [PMID: 36070471]
    LNCaP C4-2B IC50
    23.56 μM
    Compound: Enzalutamide
    Antiproliferative activity against human C4-2B cells measured after 96 hrs by celltiter-glo assay
    Antiproliferative activity against human C4-2B cells measured after 96 hrs by celltiter-glo assay
    [PMID: 30964293]
    LNCaP C4-2B IC50
    23.56 μM
    Compound: Enzalutamide
    Antiproliferative activity against human LNCaP C4-2B cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human LNCaP C4-2B cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
    [PMID: 34121397]
    PC-3 GI50
    > 10 μM
    Compound: enzalutamide
    Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 34908406]
    PC-3 IC50
    > 30 μM
    Compound: Enza
    Cytotoxicity against human PC3 assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
    Cytotoxicity against human PC3 assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
    [PMID: 31437779]
    PC-3 IC50
    > 30 μM
    Compound: Enza
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay
    [PMID: 30925341]
    PC-3 GI50
    > 40 μM
    Compound: Enzalutamide
    Antiproliferative activity against AR-negative human PC3 cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay
    Antiproliferative activity against AR-negative human PC3 cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay
    [PMID: 31271960]
    PC-3 IC50
    15.07 μM
    Compound: Enzal
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    [PMID: 30743097]
    PC-3 IC50
    24.63 μM
    Compound: Enzalutamide
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 35259487]
    PC-3 IC50
    53.38 μM
    Compound: Enzalutamide
    Antiproliferative activity against human PC3 cells measured after 72 hrs by celltiter-glo assay
    Antiproliferative activity against human PC3 cells measured after 72 hrs by celltiter-glo assay
    [PMID: 30964293]
    PC-3 GI50
    9.15 μM
    Compound: MDV3100
    Growth inhibition of human PC3 cells by MTT assay
    Growth inhibition of human PC3 cells by MTT assay
    [PMID: 25634130]
    VCaP IC50
    > 30 μM
    Compound: Enzalutamide
    Antiproliferative activity against human VCaP cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay
    Antiproliferative activity against human VCaP cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay
    [PMID: 29758518]
    VCaP GI50
    > 40 μM
    Compound: Enzalutamide
    Antiproliferative activity against AR-positive human VCaP cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay
    Antiproliferative activity against AR-positive human VCaP cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay
    [PMID: 31271960]
    VCaP GI50
    0.61 μM
    Compound: 3, MDV3100
    Growth inhibition of human VCaP cells after 144 hrs by SRB assay
    Growth inhibition of human VCaP cells after 144 hrs by SRB assay
    [PMID: 25121586]
    VCaP IC50
    149 nM
    Compound: 1; MDV-3100
    Antiproliferative activity against human VCaP cells expressing wild-type androgen receptor assessed as reduction in cell viability incubated for 5 days in presence of R1881 by CellTiter-glo assay
    Antiproliferative activity against human VCaP cells expressing wild-type androgen receptor assessed as reduction in cell viability incubated for 5 days in presence of R1881 by CellTiter-glo assay
    [PMID: 33470111]
    VCaP IC50
    149 nM
    Compound: 1; MDV-3100
    Antiproliferative activity against human VCaP cells expressing wild type AR assessed as reduction in R1881-stimulated cell proliferation measured after 5 days by Celltiter-Glo luminescence assay
    Antiproliferative activity against human VCaP cells expressing wild type AR assessed as reduction in R1881-stimulated cell proliferation measured after 5 days by Celltiter-Glo luminescence assay
    [PMID: 34422225]
    VCaP IC50
    24.47 μM
    Compound: 2a
    Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining-based fluorescence assay
    Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining-based fluorescence assay
    [PMID: 30108852]
    VCaP IC50
    3.66 μM
    Compound: Enzal
    Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by MTS assay
    Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by MTS assay
    [PMID: 30743097]
    VCaP IC50
    364 nM
    Compound: Enzalutamide
    Antiproliferative activity against AR- positive human VCaP cells incubated for 7 days in presence of AR agonist, R1881 by WST-8 assay
    Antiproliferative activity against AR- positive human VCaP cells incubated for 7 days in presence of AR agonist, R1881 by WST-8 assay
    [PMID: 31804827]
    VCaP IC50
    393 nM
    Compound: Enzalutamide
    Growth inhibition of human VCaP cells assessed as cell viability by WST-8 assay
    Growth inhibition of human VCaP cells assessed as cell viability by WST-8 assay
    [PMID: 34473519]
    VCaP IC50
    394 nM
    Compound: 2
    Growth inhibition of human VCaP cells assessed as cell viability measured after 4 days in presence of R1881 by WST-8 assay
    Growth inhibition of human VCaP cells assessed as cell viability measured after 4 days in presence of R1881 by WST-8 assay
    [PMID: 34431670]
    VCaP IC50
    53 μM
    Compound: 2; MDV3100
    Antiproliferative activity against human VCaP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay
    Antiproliferative activity against human VCaP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay
    [PMID: 31288149]
    VCaP IC50
    53.04 μM
    Compound: 4
    Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay
    Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay
    [PMID: 27301368]
    VCaP IC50
    53.04 μM
    Compound: 5; MDV3100; Xtandi; Enzalutamide
    Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay
    Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay
    [PMID: 27131065]
    VCaP IC50
    87.4 nM
    Compound: 4
    Cytotoxicity against AR-positive human VCaP cells assessed as inhibition of cell growth incubated for 7 days in presence of AR agonist, R1881 in charcoal stripped medium by WST-8 assay
    Cytotoxicity against AR-positive human VCaP cells assessed as inhibition of cell growth incubated for 7 days in presence of AR agonist, R1881 in charcoal stripped medium by WST-8 assay
    [PMID: 30629437]
    In Vitro

    Enzalutamide (MDV3100) has greater affinity to AR than ICI 176334 does in a competition assay with 16β-[18F]fluoro-5α-DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide inhibits the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys)[1].
    Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Enzalutamide (MDV3100) induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg[1].
    Enzalutamide shows dose-independent pharmacokinetics at intravenous and oral doses of 0.5-5 mg/kg[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    464.44

    Formula

    C21H16F4N4O2S

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    S=C(N(C(C1(C)C)=O)C2=CC=C(C#N)C(C(F)(F)F)=C2)N1C3=CC(F)=C(C(NC)=O)C=C3

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 50 mg/mL (107.66 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1531 mL 10.7657 mL 21.5313 mL
    5 mM 0.4306 mL 2.1531 mL 4.3063 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  1% Tween-80 in PBS

      Solubility: 10 mg/mL (21.53 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.96%

    References
    Cell Assay
    [1]

    LNCaP cells (107 cells/condition) are grown in RPMI media supplemented with 5% charcoalstripped serum for 22 days, then treated with DMSO or 1 nM R1881, combined with an antiandrogen (DMSO, 1 μM ICI 176334, 10 μM ICI 176334, 1 μM RD162, 10 μM RD162, 1 μM MDV3100, or 10 μM MDV3100) for 8 hours. An aliquot of cells are harvested for qRT-PCR of PSA and TMPRSS2 mRNA. The remaining cells are cross-linked using 1% paraformaldehyde for 10 minutes, then glycine is added and samples centrifuged (4°C, 4000 rpm, 5 minutes) to stop further crosslinking. Chromatin immunoprecipitation is performed using a chromatin immunoprecipitation assay kit. Immunoprecipitated DNA is amplified by real-time PCR. Primers are PSA enhancer forward-ATGTTCACATTAGTACACCTTGCC and reverse-TCTCAGATCCAGGCTTGCTTACTGTC and TMPRSS2 enhancer forward-TGGTCCTGGATGATAAAAAAAGTTT and reverse-GACATACGCCCCACAACAGA[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3][4]

    Mice[3]
    Following a 5-day acclimation period, 5- to 9-week-old male CB17SCID mice are castrated and allowed to recover for an additional 5 days before inoculation with tumor cells. LNCaP cells co-expressing exogenous AR and the AR-dependent reporter construct ARR2-Pb-Luc (LNCaP-AR-Lux cells) are used to generate a xenograft model of human prostate cancer. Before implantation, LNCaP-AR-Lux cells are prepared by the addition of trypsin-EDTA, washed with complete medium, collected and resuspended at 20×106 cells/mL. Cell suspensions are diluted with Matrigel to 2×106 cells/0.2 mL and delivered subcutaneously in the suprascapular region. Tumor growth is monitored to the volume of 100 mm3 when treatment begins (80 days). The observed rate of tumor take with LNCaP-AR-Lux cells is between 70% and 80%. Body weight and tumor volumes (width2×length/2) are measured two to three times per week with a digital caliper, and the average tumor volumes are determined. Test drugs are diluted in Tween 80:PEG 400, and stored at 4°C until administration by oral gavage. Each group of mice (n=7) is treated daily for 28 consecutive days with 1, 10, or 50 mg/kg Enzalutamide, vehicle control, or 50 mg/kg ICI 176334. At the end of the treatment period or when tumor volume exceeded 1,000 mm3, animals are euthanized and blood and tissue samples are collected for analysis.
    Rats[4]
    Male SD rats (n=3) are administered Enzalutamide through the tail vein (intravenous) and by oral gavage at 1 mg/kg and are kept in metabolic cages after dosing. Urine and feces samples are collected over the following time intervals after dosing: 0-2, 2-4, 4-6, 6-10, 10-24, 24-48, and 48-72 h. The metabolic cages are rinsed with distilled water, and residues are added to the urine samples at 72 h. To extract the Enzalutamide present in the feces, samples are shaken vigorously for 12 h with 50 % methanol.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1531 mL 10.7657 mL 21.5313 mL 53.8283 mL
    5 mM 0.4306 mL 2.1531 mL 4.3063 mL 10.7657 mL
    10 mM 0.2153 mL 1.0766 mL 2.1531 mL 5.3828 mL
    15 mM 0.1435 mL 0.7177 mL 1.4354 mL 3.5886 mL
    20 mM 0.1077 mL 0.5383 mL 1.0766 mL 2.6914 mL
    25 mM 0.0861 mL 0.4306 mL 0.8613 mL 2.1531 mL
    30 mM 0.0718 mL 0.3589 mL 0.7177 mL 1.7943 mL
    40 mM 0.0538 mL 0.2691 mL 0.5383 mL 1.3457 mL
    50 mM 0.0431 mL 0.2153 mL 0.4306 mL 1.0766 mL
    60 mM 0.0359 mL 0.1794 mL 0.3589 mL 0.8971 mL
    80 mM 0.0269 mL 0.1346 mL 0.2691 mL 0.6729 mL
    100 mM 0.0215 mL 0.1077 mL 0.2153 mL 0.5383 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Enzalutamide
    Cat. No.:
    HY-70002
    Quantity:
    MCE Japan Authorized Agent: